Vaxcyte (PCVX) Peer Comparison
$59.91
$-1.24
(-2.03%)
As on 28-Aug-2026 13:35EDT
Market cap
$9,318 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
3.3
Div. Yield
0 %
Edit
| Vaxcyte (PCVX) | Guardant Health (GH) | Charles River Laboratories (CRL) | Bio-Techne Corp (TECH) | Summit Therapeutics - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
9,318 | 22,906 | 14,038 | 11,268 | 10,498 |
Revenue ($ Mln) |
-- | 1,183 | 3,999 | 1,215 | -- |
Net Profit ($ Mln) |
-1,064.26 | -453.44 | -238.46 | 181.86 | -856.09 |
Net Margin (%) |
-- | -38.33 | -5.96 | 14.97 | -- |
RoE (%) |
-39.10 | -- | -8.01 | 9.03 | -153.01 |
Price to Earnings |
-- | -- | -- | 62.34 | -- |
Price-To-Book |
3.31 | 55.67 | 4.88 | 5.34 | 15.73 |
Income Statement ($ Mln)
| Vaxcyte (PCVX) | Guardant Health (GH) | Charles River Laboratories (CRL) | Bio-Techne Corp (TECH) | Summit Therapeutics - ADR | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 1,183.11 | 3,998.99 | 1,215.04 | 0.00 |
|
Cost of Revenue
|
0.87 | 413.95 | 2,709.65 | 415.97 | 0.05 |
|
Gross Profit
|
-- | 633.01 | 1,225.57 | 790.27 | -0.11 |
|
Operating Expenses
|
1,164.43 | 1,239.42 | 795.54 | 547.18 | 874.79 |
|
Operating Profit (EBIT)
|
-1,165.29 | -470.26 | 493.80 | 251.89 | -874.79 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
-1,064.26 | -454.47 | -183.67 | 240.68 | -856.04 |
|
Provision for Tax
|
0.00 | -1.03 | 52.63 | 58.82 | 0.00 |
|
Profit after Tax (Net Income)
|
-1,064.26 | -453.44 | -238.46 | 181.86 | -856.09 |
|
Minority Interest
|
0.00 | 0.00 | -2.16 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | -222.13 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Vaxcyte (PCVX) | Guardant Health (GH) | Charles River Laboratories (CRL) | Bio-Techne Corp (TECH) | Summit Therapeutics - ADR | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
2,757.94 | -222.87 | 2,839.64 | 2,108.22 | 629.98 |
|
Minority Interest
|
0.00 | 0.00 | -2.16 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
108.94 | 1,796.20 | 3,508.87 | 314.81 | 18.64 |
|
Current Liabilities
|
271.28 | 338.96 | 1,134.75 | 163.70 | 103.57 |
|
Total Liabilities
|
3,045.97 | 2,013.66 | 7,135.42 | 2,557.87 | 557.50 |
Assets ($ Mln)
| Vaxcyte (PCVX) | Guardant Health (GH) | Charles River Laboratories (CRL) | Bio-Techne Corp (TECH) | Summit Therapeutics - ADR | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
1,585.49 | 547.66 | 6,003.04 | 1,842.33 | 31.61 |
|
Current Assets
|
1,552.67 | 1,364.64 | 1,529.11 | 744.40 | 720.58 |
|
Total Assets
|
3,045.97 | 2,013.66 | 7,135.42 | 2,557.87 | 557.50 |
|
Total Debt*
|
115.45 | 1,697.01 | 3,027.69 | 274.15 | 20.38 |
|
Net Current Assets
|
1,281.39 | 1,025.68 | 394.36 | 0.00 | 617.01 |
Cashflow ($ Mln)
| Vaxcyte (PCVX) | Guardant Health (GH) | Charles River Laboratories (CRL) | Bio-Techne Corp (TECH) | Summit Therapeutics - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-655.58 | -184.76 | 737.65 | 287.56 | -239.67 |
|
Cash Flow from Investing Activities
|
437.35 | -627.20 | -209.32 | -35.18 | -129.37 |
|
Cash from Financing Activities
|
2.01 | 671.13 | -536.73 | -253.91 | 458.31 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Vaxcyte (PCVX) | Guardant Health (GH) | Charles River Laboratories (CRL) | Bio-Techne Corp (TECH) | Summit Therapeutics - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-24.37 | -29.66 | -2.33 | 3.03 | -263.03 |
|
ROE (%)
|
-39.10 | 348.42 | -8.01 | 8.83 | -153.01 |
|
ROA (%)
|
-30.99 | -23.73 | -2.76 | 6.00 | -173.90 |
|
EBIT Margin (%)
|
-- | -38.01 | -1.94 | 20.25 | -- |
|
Net Margin (%)
|
-- | -38.33 | -5.96 | 14.97 | -- |
|
Cash Profit Margin (%)
|
-- | 0.00 | 0.00 | 0.00 | -- |
Growth Ratios
| Vaxcyte (PCVX) | Guardant Health (GH) | Charles River Laboratories (CRL) | Bio-Techne Corp (TECH) | Summit Therapeutics - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 42.74 | -0.74 | -0.38 | -- |
|
EBIT Growth (%)
|
-113.26 | -9.76 | -178.82 | 130.05 | -10.72 |
|
Net Profit Growth (%)
|
-94.39 | -9.57 | -244.47 | 147.77 | -130.47 |
|
EPS Growth (%)
|
-81.42 | -4.67 | -266.27 | 155.17 | -122.88 |
|
Book Value Growth (%)
|
-15.46 | 31.44 | -13.87 | 9.00 | 321.10 |
Valuation Ratios
| Vaxcyte (PCVX) | Guardant Health (GH) | Charles River Laboratories (CRL) | Bio-Techne Corp (TECH) | Summit Therapeutics - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-8.19 | -31.57 | -68.02 | 109.18 | -12.42 |
|
Price / Book Value
|
2.34 | -132.33 | 3.10 | 4.18 | 27.41 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-6.67 | -36.51 | 30.84 | 38.25 | -11.94 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Vaxcyte (PCVX) | Guardant Health (GH) | Charles River Laboratories (CRL) | Bio-Techne Corp (TECH) | Summit Therapeutics - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | -6.74 | 0.92 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
0.00 | -0.12 | 0.00 | 0.00 | 0.01 |
|
Current Ratio
|
5.72 | 4.03 | 1.35 | 4.55 | 6.96 |
|
Quick Ratio
|
5.72 | 3.71 | 1.04 | 3.35 | 6.96 |
|
Interest Coverage
|
-- | -93.37 | -0.73 | 45.53 | -- |
Operating Efficiency Ratios
| Vaxcyte (PCVX) | Guardant Health (GH) | Charles River Laboratories (CRL) | Bio-Techne Corp (TECH) | Summit Therapeutics - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 12.19 | 17.80 | 17.83 | -- |
|
Asset Turnover
|
0.00 | 0.62 | 0.46 | 0.40 | 0.00 |
|
Receivable days
|
-- | 46.14 | 65.03 | 67.12 | -- |
|
Inventory Days
|
-- | 82.13 | 37.81 | 157.03 | -- |
|
Payable days
|
-- | 48.66 | 18.93 | 26.92 | 31,626.28 |
|
Cash Conversion Cycle
|
-- | 79.61 | 83.91 | 197.23 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
